Pfizer is planning to introduce a new JAK inhibitor after ‘Xeljanz’ to Korea. However, the new drug will target the ‘atopic dermatitis’ treatment market.

According to industry sources, Pfizer Korea has recently submitted an application requesting marketing authorization for its Cibinqo (abrocitinib). The approval is expected to be made in the first half of next year.

The drug, which is taken once daily, has been approved for the treatment of moderate-to-severe atopic dermatitis (AD) in adults and adolescents aged 12 years and over that are candidates for systemic therapy. The drug has not received marketing authorization in the U.S yet.

Cibinqo is a selective Janus ki